MK-3614

Merck Sharp & Dohme LLC · Phase 1 active Small molecule

At a glance

Generic name	MK-3614
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Multiple Dose Study of MK-3614 (MK-3614-002) (PHASE1)
A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-3614 CI brief — competitive landscape report
MK-3614 updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI